Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | CHRM2 | P08172 | 7/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 6/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 5/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 5/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Propylene Oxide SCHEMBL5693327 | 0.80 | TSHR (0.81) | TSHRCHRM2CHRM3CHRM4CHRM1 | |
| SCHEMBL8768251 | 0.80 | TSHR (0.48) | TSHRCHRM2CHRM3CHRM4CHRM1 | |
| SCHEMBL18387696 | 0.80 | TSHR (0.48) | TSHRCHRM2CHRM3CHRM4CHRM1 | |
| SCHEMBL17172100 | 0.80 | CHRNA7 (0.41) | TSHRMEN1KMT2ASLC6A2HTR2B | |
| SCHEMBL8768288 | 0.80 | TSHR (0.48) | TSHRCHRM2CHRM3CHRM4CHRM1 | |
| SCHEMBL21363715 | 0.80 | KDM1A (0.39) | TSHRSLC6A2HTR2BSLC6A3 | |
| SCHEMBL21363517 | 0.80 | CHRNA7 (0.41) | TSHRMEN1KMT2ASLC6A2HTR2B | |
| SCHEMBL21363398 | 0.80 | CHRNA7 (0.41) | TSHRMEN1KMT2ASLC6A2HTR2B | |
| SCHEMBL21393372 | 0.80 | KDM1A (0.39) | TSHRSLC6A2HTR2BSLC6A3 | |
| SCHEMBL1396587 | 0.80 | TSHR (0.48) | TSHRCHRM2CHRM3CHRM4CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2917194-B1 | NOVEL BENZYL SULFONAMIDE COMPOUNDS USEFUL AS MOGAT-2 INHIBITORS | LILLY CO ELI (US) | 2017-09-27 | — | — | EP | disclosed |
| US-9416138-B2 | Benzyl sulfonamide compounds useful as MoGAT-2 inhibitors | ELI LILLY AND COMPANY (US) | 2016-08-16 | — | — | US | disclosed |
| US-20150284404-A1 | NOVEL BENZYL SULFONAMIDE COMPOUNDS USEFUL AS MOGAT-2 INHIBITORS | ELI LILLY AND COMPANY | 2015-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284404-A1 | NOVEL BENZYL SULFONAMIDE COMPOUNDS USEFUL AS MOGAT-2 INHIBITORS | MOGAT2, SOAT1, SOAT2 | TSHR 2001/4885CHRM2 3908/4885CHRM3 4565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.